PUBLIC COMPANY
saveConcerto Biosciences Inc
updated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1Topical ENS-002 for Atopic Dermatitis in Adults
- phase2A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
- phase2A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia
- phase3Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)
🐶 Hiring Signal
News
- Kolon TissueGene cuts 37 US staffers after Phase 3 failFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffersAs always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.fiercebiotech · 8mo ago
comments(0)
5-min edit window · permanent after that